Gilbert Lynn Marks - 24 Mar 2022 Form 3 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Director
Signature
/s/ Lucy Day, Attorney-in-Fact for Gilbert Lynn Marks
Issuer symbol
ANTX
Transactions as of
24 Mar 2022
Net transactions value
$0
Form type
3
Filing time
24 Mar 2022, 21:22:18 UTC
Next filing
16 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ANTX Common Stock 22,830 24 Mar 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ANTX Stock Option (right to buy) 24 Mar 2022 Common Stock 10,665 $6.60 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 10,563 of the shares are subject to repurchase by the Issuer.
F2 The shares subject to the option vest as follows: 1/36th of the shares vests monthly over three years from April 30, 2021, subject to the Reporting Person's continuous service as of such date.

Remarks:

Exhibit 24 - Power of Attorney